Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Likely Canopy-Acreage Deal Looks Good Enough To Boost ETF MJ

Published 04/18/2019, 01:00 AM
Updated 07/09/2023, 06:31 AM

Marijuana market is all about inorganic expansion of late. Loads of acquisitions and partnerships have been done in the past year. Talks are now making rounds that Canopy Growth (NYSE:CGC) could purchase the rights to buy Acreage Holdings ACRGF when (or if) marijuana becomes federally legal in the United States at an agreed-upon price, as noted on markerwatch. This acquisition, if it happens, would mark the first key cross-border marijuana deal.

As per sources, the purchase deal could be announced as soon as this week, though nothing is finalized at the time of writing. Acreage shares gained 9.1% and Canopy Growth jumped 2.8% on Apr 17. Canopy shares added a further 6.8% after hours.

Acreage Holdings is one of the largest vertically integrated, multistate cannabis operators in the United States. Canopy is a big name in the space with a market cap of about $14.70 billion. Last August, U.S.-based Constellation Brands (NYSE:STZ) — a leading producer of alcoholic beverages — announced an expansion of its stake in Canopy. The investment was worth about $4 billion. The move corroborates the worth of Canopy Growth as a company (read: Follow Constellation Brands, Bet Big on Cannabis ETFs).

Long-Term Potential of the Deal

Canada has been at the center in cannabis investing as recreational marijuana was legalized there is last October. The legal market for marijuana is way larger in the United States, where sales were about $10.4 billion last year while Canada’s market was worth $1.6 billion. Overall, the North America market grew 30% last year. Another source had noted last April that the U.S. legal marijuana market is expected to witness a CAGR of 24.9% from 2017 to 2025.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Per industry experts, American multistate operators continue to stretch their U.S. market footprint, while the Canadian companies are looking to expand their territory internationally by purchasing foreign assets inexpensively. With the possible legalization of cannabis on the federal level some point down the line and the companies’ increased access to the capital markets, the U.S. market is the new name of the game since Canada’s growth story looks a bit priced-in.

Flurry of Deals Taking Place in the Industry

Aurora Cannabis (TO:ACB) made some other big acquisitions last year, including the purchase of Saskatchewan-based CanniMed Therapeutics in May and Ontario-based MedReleaf in July. In late-2018, Aurora Cannabis announced expansion in Mexico with the acquisition of Farmacias Magistrales S.A. This expansion will allow Aurora to have access to the newly legal Mexican medical marijuana market.

Moreover, there were deals like Aphria’s (TO:APHA) purchase of Nuuvera in March 2018 and Canopy Growth’s acquisition announcement of U.S.-based Ebbu Hemp. In late-2018, Marlboro cigarette maker Altria Group (NYSE:MO) purchased a 45% stake in Canadian cannabis firm Cronos Group (NASDAQ:CRON) (read: 4 Reasons Why Marijuana Stocks & ETFs Could Be on a High in 2019).

In February 2019, Tilray (NASDAQ:TLRY) announced a deal to acquire the world’s largest hemp food maker Manitoba Harvest for up to C$419 million ($318 million) (read: Tilray's Deal to Buy Hemp Food Maker Bolsters Marijuana ETF).

Against this backdrop, we expect more deals to pull off the industry in the coming days.

ETF in Focus

ETFMG Alternative Harvest ETF or (SNX:MJ) is a pureplay fund in the space. The fund is down 11.1% in the past month. But given the companies’ euphoria for deals, investors can cash in on the beaten down price. However, the fund has added 36.7% this year.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The underlying Prime Alternative Harvest Index of the fund enables investors to take advantage of both event-driven news and long-term trends in the cannabis industry. Aurora (9.73%), GW Pharmaceuticals (9.0%) and Canopy Growth (6.7%) hold the top three spots in the fund, which charges 75 bps in fees.

Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>



Constellation Brands Inc (STZ): Free Stock Analysis Report

Altria Group, Inc. (MO): Free Stock Analysis Report

Canopy Growth Corporation (CGC): Free Stock Analysis Report

Aphria Inc. (APHA): Free Stock Analysis Report

Cronos Group Inc. (CRON): Free Stock Analysis Report

Tilray, Inc. (TLRY): Free Stock Analysis Report

Aurora Cannabis Inc. (ACB): Free Stock Analysis Report

ETFMG Alternative Harvest ETF (MJ): ETF Research Reports

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.